Related Experiment Video
Updated: Jul 20, 2025

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
Published on: June 20, 2018
Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition
Jami Kronick1, Manal Y Gabril2, Andrew A House3
1Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Tuberous Sclerosis Complex (TSC) kidney disease can cause declining kidney function even without large tumors. Mammalian target of rapamycin (mTOR) inhibitors may improve kidney function in these cases, suggesting broader treatment potential.
Area of Science:
- Nephrology
- Genetics
- Oncology
Background:
- Tuberous Sclerosis Complex (TSC) is a genetic disorder associated with benign tumors, particularly angiomyolipomas (AMLs) in the kidneys.
- Kidney dysfunction in TSC is often linked to large AMLs or cysts, leading to interventions that damage kidney tissue.
- Current treatment guidelines for TSC kidney disease focus on mTOR inhibitors for large AMLs.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Chronic Kidney Disease III: Interprofessional Care
PI3K/mTOR/AKT Signaling Pathway
Nephrons
Chronic Kidney Disease I: Introduction
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...

